Oppenheimer Weighs in on Frequency Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:FREQ)

Frequency Therapeutics, Inc. (NASDAQ:FREQ – Get Rating) – Equities researchers at Oppenheimer issued their Q3 2022 EPS estimates for shares of Frequency Therapeutics in a research report issued to clients and investors on Monday, May 9th. Oppenheimer analyst J. Olson anticipates that the company will earn ($0.77) per share for the quarter.

Separately, B. Riley reduced their price objective on Frequency Therapeutics from $17.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 23rd.

Shares of FREQ stock opened at $1.40 on Wednesday. Frequency Therapeutics has a 12 month low of $1.16 and a 12 month high of $10.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 11.79 and a current ratio of 9.85. The company’s 50 day moving average is $1.82. The firm has a market capitalization of $48.97 million, a P/E ratio of -0.55 and a beta of 0.96.

Frequency Therapeutics (NASDAQ:FREQ – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03).

A number of hedge funds have recently modified their holdings of FREQ. Tortoise Investment Management LLC bought a new position in Frequency Therapeutics in the first quarter worth $27,000. Duncker Streett & Co. Inc. bought a new position in shares of Frequency Therapeutics during the first quarter valued at $33,000. Citigroup Inc. lifted its holdings in shares of Frequency Therapeutics by 56.6% during the fourth quarter. Citigroup Inc. now owns 9,203 shares of the company’s stock valued at $47,000 after acquiring an additional 3,325 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Frequency Therapeutics during the first quarter valued at $54,000. Finally, Renaissance Technologies LLC bought a new position in shares of Frequency Therapeutics during the fourth quarter valued at $69,000. 50.64% of the stock is owned by hedge funds and other institutional investors.

About Frequency Therapeutics (Get Rating)

Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.

Featured Articles